NASDAQ
28.33USD
+0.22 (+0.78%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.1B
P/E
—
EPS
—
Beta
0.00
52W range
16.12-35.29
Day range
28.00–28.93
Open
28.34
Prev close
28.11
Volume
53.4K
Avg volume
431.6K
Dividend
0.00
IPO
2026-07-29
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Apnimed, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for APMD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
